MORRISTOWN, N.J., Nov. 11, 2011 /PRNewswire/ -- Actavis, an international generic pharmaceutical company, today announced that it has begun shipping Morphine Sulfate Extended-Release Capsules, USP CII, an authorized generic of KADIAN®*.
Actavis has been manufacturing KADIAN® for 15 years and has in-depth expertise in the development and manufacturing of complex controlled-release pharmaceuticals.
KADIAN® US sales have grown 50% in the last 5 years to approximately $275 million for the 12 months ending September 30, 2011, according to IMS Health.
Please see full prescribing information at www.actavis.us/morphinesulfate
Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL. Please visit www.actavis.us for more information.
*KADIAN ® is a registered trademark of Actavis Elizabeth LLC.
Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial succes
|SOURCE Actavis Inc.|
Copyright©2010 PR Newswire.
All rights reserved